ADVERTISEMENT
Pathways Disruptors in Ovarian Cancer
Pathways Disruptors, a series hosted by Journal of Clinical Pathways, reviews key findings and takeaways of the latest research in oncology, focusing on the potential impact of new data on current pathway programs.
Winston Wong, PharmD, Editor-in-Chief of the Journal of Clinical Pathways, discusses the final read-out of the ATHENA-MONO trial, an international, randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib as first-line maintenance treatment across a diverse patient population with newly diagnosed ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement